P2RX4

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, P2RX4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated P2RX4 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher P2RX4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated P2RX4 expression acts as an unfavorable survival marker.

LUSC, KIRP, and BRCA are the cancer types where P2RX4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
LUSCOSMedianII,III,IV0.2110.634.00518view →
KIRPOSMedianAll0.2720.885<.00112view →
BRCADFSMedianAll0.2940.903<.0016view →
Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

P2RX4–LUSC (OS)

Kaplan–Meier survival curve for P2RX4 mutant vs wild-type samples in LUSC.

Open the LUSC breakdown →

Exploration